FDA adverse event reports on statin-associated rhabdomyolysis

OBJECTIVE: To determine the number of cases of statin-associated rhabdomyolysis reported to the Food and Drug Administration for 6 statins and to profile the cases. METHODS: A retrospective analysis of all domestic and foreign reports of statin-associated rhabdomyolysis between November 1997 and March 2000 was conducted. Outcome measures included the total number of reports (initial plus follow-up), the number of unique cases, age, gender, percentages of report codes and role codes, and frequencies of concomitant interacting drugs that may have precipitated rhabdomyolysis, outcomes codes, and report source codes. RESULTS: There were 871 reports of statin-associated rhabdomyolysis in the 29-month time frame examined, representing 601 cases. The following number of cases were associated with each of the individual statins: simvastatin, 215 (35.8%); cerivastatin, 192 (31.9%); atorvastatin, 73 (12.2%); pravastatin, 71 (11.8%); lovastatin, 40 (6.7%); and fluvastatin, 10 (1.7%). Drugs that may have interacted with the statins were present in the following number of cases: mibefradil (n = 99), fibrates (n = 80), cyclosporine (n = 51), macrolide antibiotics (n = 42), warfarin (n = 33), digoxin (n = 26), and azole antifungals (n = 12). The reports of 62.1% of cases were classified as expedited. Statins were designated as the primary suspect in 72.0% of the cases. Death was listed as the outcome in 38 cases. The majority of reports (n = 556) were from health professionals. CONCLUSIONS: Compared with the other statins, simvastatin and cerivastatin were implicated in a relatively higher number of reports. Because of the various limitations of a spontaneous reporting-system database, caution is urged when interpreting the relative number of cases reported.

This article has been cited by other articles:

				K. Sakamoto, T. Honda, S. Yokoya, S. Waguri, and J. Kimura Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers FASEB J, December 1, 2007; 21(14): 4087 - 4094. [Abstract] [Full Text] [PDF]

				B. Najafian, D. B. Franklin, and A. B. Fogo Acute Renal Failure and Myalgia in a Transplant Patient J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2870 - 2874. [Abstract] [Full Text] [PDF]

				A. Watanabe, K. Nakamura, N. Okudaira, O. Okazaki, and K.-i. Sudo Risk Assessment for Drug-Drug Interaction Caused by Metabolism-Based Inhibition of CYP3A Using Automated in Vitro Assay Systems and Its Application in the Early Drug Discovery Process Drug Metab. Dispos., July 1, 2007; 35(7): 1232 - 1238. [Abstract] [Full Text] [PDF]

				J. Jose, K. Saravu, and B. A. Shastry Atorvastatin-induced early-onset rhabdomyolysis in a patient with nephrotic syndrome Am. J. Health Syst. Pharm., April 1, 2007; 64(7): 726 - 729. [Abstract] [Full Text] [PDF]

				H. Akoglu, R. Yilmaz, A. Kirkpantur, M. Arici, B. Altun, and C. Turgan Combined Organ Failure with Combination Antihyperlipidemic Treatment: A Case of Hepatic Injury and Acute Renal Failure Ann. Pharmacother., January 1, 2007; 41(1): 143 - 147. [Abstract] [Full Text] [PDF]

				J. R Burton, I. Burton, and G. J Pearson Clopidogrel-Precipitated Rhabdomyolysis in a Stable Heart Transplant Patient Ann. Pharmacother., January 1, 2007; 41(1): 133 - 137. [Abstract] [Full Text] [PDF]

				P. J. Barter and K.-A. Rye The Argument Against the Appropriateness of Over-the-Counter Statins Circulation, September 19, 2006; 114(12): 1315 - 1320. [Full Text] [PDF]

				R. Arora, M. Liebo, and F. Maldonado Statin-Induced Myopathy: The Two Faces of Janus Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2006; 11(2): 105 - 112. [Abstract] [PDF]

				R. Nowack and B. Nowak Herbal teas interfere with cyclosporin levels in renal transplant patients Nephrol. Dial. Transplant., November 1, 2005; 20(11): 2554 - 2556. [Full Text] [PDF]

				J. Chan, R. L Hui, and E. Levin Differential Association Between Statin Exposure and Elevated Levels of Creatine Kinase Ann. Pharmacother., October 1, 2005; 39(10): 1611 - 1615. [Abstract] [Full Text] [PDF]

				G. R. Bailie, J. A. Clark, C. E. Lane, and P. L. Lane Hypersensitivity reactions and deaths associated with intravenous iron preparations Nephrol. Dial. Transplant., July 1, 2005; 20(7): 1443 - 1449. [Abstract] [Full Text] [PDF]

				S. M. Grundy The Issue of Statin Safety: Where do We Stand? Circulation, June 14, 2005; 111(23): 3016 - 3019. [Full Text] [PDF]

				S. S Tomlinson and K. K Mangione Potential Adverse Effects of Statins on Muscle Physical Therapy, May 1, 2005; 85(5): 459 - 465. [Full Text] [PDF]

				S.-H. Hsiao, C.-M. Chang, C.-J. Tsao, Y.-Y. J Lee, M.-Y. Hsu, and T.-J. Wu Acute Rhabdomyolysis Associated with Ofloxacin/Levofloxacin Therapy Ann. Pharmacother., January 1, 2005; 39(1): 146 - 149. [Abstract] [Full Text] [PDF]

				D. J. Graham, J. A. Staffa, D. Shatin, S. E. Andrade, S. D. Schech, L. La Grenade, J. H. Gurwitz, K. A. Chan, M. J. Goodman, and R. Platt Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering Drugs JAMA, December 1, 2004; 292(21): 2585 - 2590. [Abstract] [Full Text] [PDF]

				W. A Prescott Jr, D.-a. D Streetman, and D. S Streetman The Potential Role of HMG-CoA Reductase Inhibitors in Pediatric Nephrotic Syndrome Ann. Pharmacother., December 1, 2004; 38(12): 2105 - 2114. [Abstract] [Full Text] [PDF]

				E. A. Meagher Addressing Cardiovascular Disease in Women: Focus on Dyslipidemia J Am Board Fam Med, November 1, 2004; 17(6): 424 - 437. [Abstract] [Full Text] [PDF]

				T. C. Sarich, K.-M. Schutzer, H. Dorani, U. Wall, I. Kalies, L. Ohlsson, and U. G. Eriksson No Pharmacokinetic or Pharmacodynamic Interaction Between Atorvastatin and the Oral Direct Thrombin Inhibitor Ximelagatran J. Clin. Pharmacol., August 1, 2004; 44(8): 928 - 934. [Abstract] [Full Text] [PDF]

				T. Morera, G. Gervasini, J. A Carrillo, and J. Benitez Using a Computerized Drug Prescription Screening System to Trace Drug Interactions in an Outpatient Setting Ann. Pharmacother., July 1, 2004; 38(7): 1301 - 1306. [Abstract] [Full Text] [PDF]

				S. Bellosta, R. Paoletti, and A. Corsini Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions Circulation, June 15, 2004; 109(23_suppl_1): III-50 - III-57. [Abstract] [Full Text]

				L. Roten, R. A Schoenenberger, S. Krahenbuhl, and R. G Schlienger Rhabdomyolysis in Association with Simvastatin and Amiodarone Ann. Pharmacother., June 1, 2004; 38(6): 978 - 981. [Abstract] [Full Text] [PDF]

				W. Insull Jr, M. E. McGovern, H. Schrott, P. Thompson, J. R. Crouse, F. Zieve, and J. Corbelli Efficacy of Extended-Release Niacin With Lovastatin for Hypercholesterolemia: Assessing All Reasonable Doses With Innovative Surface Graph Analysis Arch Intern Med, May 24, 2004; 164(10): 1121 - 1127. [Abstract] [Full Text] [PDF]

				J. McKenney New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders Arch Intern Med, April 12, 2004; 164(7): 697 - 705. [Abstract] [Full Text] [PDF]

				R. R. Johi, R. Mills, P. J. Halsall, and P. M. Hopkins Anaesthetic management of coronary artery bypass grafting in a patient with central core disease and susceptibility to malignant hyperthermia on statin therapy Br. J. Anaesth., November 1, 2003; 91(5): 744 - 747. [Abstract] [Full Text] [PDF]

				A. Shaukat, M. Benekli, G. D Vladutiu, J. L Slack, M. Wetzler, and M. R Baer Simvastatin-Fluconazole Causing Rhabdomyolysis Ann. Pharmacother., July 1, 2003; 37(7): 1032 - 1035. [Abstract] [Full Text] [PDF]

				B. E Sipe, R. J Jones, and G. H Bokhart Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction Ann. Pharmacother., June 1, 2003; 37(6): 808 - 811. [Abstract] [Full Text] [PDF]

				P. D. Thompson, P. Clarkson, and R. H. Karas Statin-Associated Myopathy JAMA, April 2, 2003; 289(13): 1681 - 1690. [Abstract] [Full Text] [PDF]

				C. M. Ballantyne, A. Corsini, M. H. Davidson, H. Holdaas, T. A. Jacobson, E. Leitersdorf, W. Marz, J. P. D. Reckless, and E. A. Stein Risk for Myopathy With Statin Therapy in High-Risk Patients Arch Intern Med, March 10, 2003; 163(5): 553 - 564. [Abstract] [Full Text] [PDF]